Combination of lapatinib and trastuzumab shrinks HER2 positive breast cancer significantly in 11 days after diagnosis
Thursday, March 10, 2016 - 13:30
in Health & Medicine
Approximately a quarter of women with HER2 positive breast cancer, who were treated with a combination of the targeted drugs lapatinib and trastuzumab before surgery and chemotherapy, saw their tumors shrink significantly or even disappear, according to results from a clinical trial.